Amended Current Report Filing (8-k/a)
May 08 2020 - 4:07PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
Third
Amendment
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): March
6, 2020
Kiwa
Bio-Tech Products Group Corporation
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
000-33167
|
|
77-0632186
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
3200
Guasti Road, Suite 100
Ontario,
CA
|
|
91761
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (626) 715-5855
(Former
name or former address, if changed since last report)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of exchange on which registered
|
Common
Stock par value $0.001
|
|
KWBT
|
|
OTCQB
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4 (c) under
the Exchange Act (17 CFR 240.13(c)
|
Explanatory
Note
The
Company’s Amended Form 8-K updates the Company’s previously Form 8-K filed on March 6, 2020 (and amended on March
30, 2020 May 7, 2020). It corrects a typographical error.
TABLE
OF CONTENTS
Item
8.01 Other Events.
On
March 4, 2020, the U.S. Securities and Exchange Commission (the “Commission”) issued an order under Section 36 (Release
No. 34-88318) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), granting exemptions from specified
provisions of the Exchange Act and certain rules thereunder (the “Order”). The Order provides that a registrant subject
to the reporting requirements of Exchange Act Section 13(a) or 15(d), and any person required to make any filings with respect
to such a registrant, is exempt from any requirement to file or furnish materials with the Commission under Exchange Act Sections
13(a), 13(f), 13(g), 14(a), 14(c), 14(f), 15(d) and Regulations 13A, Regulation 13D-G (except for those provisions mandating the
filing of Schedule 13D or amendments to Schedule 13D), 14A, 14C and 15D, and Exchange Act Rules 13f-1, and 14f-1, as applicable,
where certain conditions are satisfied.
Kiwa
Bio-Tech Products Group Corporation (the “Company”) originally filed a Form 8-K regarding the coronavirus’ potential
impact on its business and its ability to timely file its Form 10-K Annual Report for the period ended December 31, 2019. We are
furnishing this Amended Current Report on Form 8-K/A to indicate our reliance on the Order in connection with the Company’s
Annual Report on Form 10-K for the year ended December 31, 2019 as a result of the circumstances set forth below.
As
previously announced in its Form 8-K filed on March 6, 2020 (and amended on March 30, 2020), the preparation of the Company’s
Annual Report including financial statements and completion of the auditing process has been delayed by Chinese Government-imposed
quarantines, office closings and travel restrictions which affect both the Company’s and its service provider’s personnel.
Specifically, the Company has significant operations in the city of Yangling, Shaanxi Province, China. Due to concerns related
to the spread of the Coronavirus, the entire city of Yangling was locked down by the Government of China since January 25, 2020
and has only recently re-opened. Until recently, all of the Company’s employees in this area have been required by the Government
to stay at home until further notice, subject to the containment of the Coronavirus. In compliance with the Government’s
health emergency rules in place, the Company’s building has been temporarily closed since January 19, 2020 and, until recently,
people were not allowed to enter the office and to access certain of the Company’s business records located in it. Due to
Government-imposed quarantines, office closings and travel restrictions affecting the Company’s personnel and service providers,
the Company’s accounting department has been unable to process certain of its accounting records and receipts on a timely
basis as required to complete the audit of the Company’s financial statements.
These
unforeseen circumstances have resulted in the Company being unable to timely file an accurate Annual Report on Form 10-K for its
year-ended December 31, 2019 by the prescribed date without undue hardship and expense to the Company. Accordingly, in reliance
upon the Order, the Company has requested an additional extension of the filing deadline for the Form 10-K from May 15, 2020 to
June 1, 2020.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
May 8, 2020
|
Kiwa
Bio-Tech Products Group Corporation
|
|
|
|
|
/s/
Wade Li
|
|
By:
|
Wade
Li
|
|
Title:
|
Chief
Executive Officer
|
Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From Sep 2023 to Sep 2024